Du 123015

Drug Profile

Du 123015

Latest Information Update: 19 Jan 2007

Price : $50

At a glance

  • Originator Solvay
  • Class
  • Mechanism of Action Serotonin receptor agonists; Serotonin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 27 Jul 1999 No-Development-Reported for Depression in Belgium (Unknown route)
  • 27 Jul 1999 No-Development-Reported for Anxiety disorders in Belgium (Unknown route)
  • 28 Feb 1997 Phase-II clinical trials for Anxiety disorders in Belgium (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top